ALX Oncology (ALXO)
Develops evorpacept and ALX2004 for clinical-stage cancer studies.
$2.01
Pre-market−0.07 (−3.37%)
At close$2.08(+5.05%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions72 holders · as of Mar 31, 2026 | 68.17% | 94.27M shares | |
| Insiders8 holders · as of Aug 18, 2026 | 10.37% | 14.33M shares | |
| Strategic holders2 holders · as of May 15, 2026 | 10.92% | 15.10M shares | |
| Otherremainder | 10.54% | 14.58M shares |
138.28M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
72 holders · 94.27M shares · 26 new positions · 44 increased · 11 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 13.01M | 9.41% | +13.01Mnew | May 15, 2026 |
| Ra Capital Management, L.P. | 13.01M | 9.41% | +13.01Mnew | May 15, 2026 |
| Venbio Partners LLC | 12.88M | 9.32% | +3.18M | May 15, 2026 |
| Redmile Group, LLC | 7.96M | 5.76% | +4.70M | May 15, 2026 |
| Blackstone Inc. | 5.83M | 4.21% | +5.83Mnew | May 15, 2026 |
| Driehaus Capital Management LLC | 5.73M | 4.15% | +4.31M | May 15, 2026 |
| Vanguard Capital Management LLC | 4.18M | 3.02% | +4.18Mnew | May 15, 2026 |
| Marshall Wace, LLP | 3.76M | 2.72% | +3.73M | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Goodman Corey Sincl. venBio Global Strategic GP, L.P., venBio Global Strategic Fund, L.P. +5 more | 10.00% | 13.16M | 13D | Feb 4, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 13.12M | 13G | Feb 9, 2026 ↗ |
| Redmile Group, LLC | 6.80% | 9.21M | 13G | May 15, 2026 ↗ |
| HBM Healthcare Investments (Cayman) Ltd. | 6.50% | 8.59M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.40% | 7.33M | 13G | Jul 27, 2026 ↗ |
| Millennium Management LLC | 5.10% | 2.71M | 13G | Oct 8, 2025 ↗ |
| TCG Crossover GP II, LLC | 5.00% | 6.51M | 13G | Feb 6, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Shelly Wongofficer: SVP, FINANCE AND CAO | Sale | 573 | $1.93 | 87,828 |
| Aug 17, 2026 | Jason Lettmanndirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 2,230 | $1.93 | 294,379 |
| Jul 1, 2026 | Shelly Wongofficer: SVP, FINANCE AND CAO | Sale | 1,404 | $2.04 | 88,401 |
| Mar 19, 2026 | Shelly Pintoofficer: SVP, FINANCE AND CAO | Sale | 903 | $2.17 | 86,805 |
| Mar 19, 2026 | Jason Lettmanndirector, officer: CHIEF EXECUTIVE OFFICER | Sale | 12,311 | $2.17 | 293,609 |
| Feb 18, 2026 | Shelly Pintoofficer: SVP, FINANCE AND CAO | Sale | 565 | $2.27 | 87,708 |
| Feb 2, 2026 | Corey S. Goodmandirector, 10 percent owner: | Purchase | 3,184,713 | $1.57 | 8,453,038 |
| Jan 6, 2026 | Shelly Pintoofficer: SVP, FINANCE AND CAO | Sale | 3,925 | $1.11 | 88,273 |
| Sep 16, 2025 | Jason Lettmanndirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 21,070 | $1.07 | 233,958 |
| Sep 17, 2025 | Jason Lettmanndirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 71,163 | $1.08 | 305,121 |
CongressHouse and Senate disclosures
Not reported.